Cefuroxime, an antibiotic, reduces the activity of an enzyme in muscle and other tissues that converts one thyroid hormone into a more active form, without affecting similar enzymes, which may allow targeted control of thyroid hormone levels in specific areas of the body.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of all existing in vitro and in vivo studies on cefuroxime and deiodinase inhibition would establish whether the observed D2 suppression is reproducible across models and doses.
A systematic review and meta-analysis of all peer-reviewed studies reporting D2 enzyme activity after cefuroxime exposure in human cell lines, rodent tissues, and ex vivo tissue explants, with standardized assays, dose-response curves, and statistical pooling of effect sizes across studies.
An RCT in humans with hyperthyroidism would determine whether cefuroxime administration reduces tissue T3 levels and improves clinical symptoms compared to placebo.
A double-blind, placebo-controlled trial of 100 adults with confirmed Graves' disease, randomized to receive 500 mg oral cefuroxime twice daily or placebo for 8 weeks, measuring serum free T3, tissue T3 via PET tracer, TSH suppression, and symptom scores as primary endpoints.
A prospective cohort could assess whether long-term antibiotic use including cefuroxime correlates with altered thyroid hormone metabolism in large populations.
A prospective cohort of 10,000 adults with documented cefuroxime prescriptions over 5 years, matched to non-users, measuring annual serum TSH, free T4, free T3, and deiodinase activity biomarkers to assess longitudinal associations.
Could test whether prior cefuroxime exposure is more common in individuals with unexplained low tissue T3 levels compared to controls.
A case-control study comparing 200 patients with idiopathic low tissue T3 (confirmed by biomarkers) to 400 matched controls, assessing prior cefuroxime use within the past 6 months via pharmacy records and clinical history.
Could identify whether individuals recently treated with cefuroxime show lower serum T3/T4 ratios compared to those not treated.
A cross-sectional analysis of 500 adults undergoing thyroid function testing within 7 days of cefuroxime discontinuation, compared to 500 matched controls without recent antibiotic exposure, measuring serum TSH, free T4, free T3, and reverse T3.